Reslizumab

Synonyms: 瑞利珠单抗; Sch 55700; CDP-835; JES1-39D10
Reslizumab (Sch 55700) 是一种靶向人白介素 5 (IL-5) 的人源化单克隆抗体,用于研究嗜酸性粒细胞性哮喘,可有效阻断 IL-5 的功能,并对人 IL-5 具有高结合亲和力,在 Biacore 表面等离振子共振和动力学排斥分析中 KD 值分别为 109 pM 和 4.3 pM。
产品编号: MS-I91171 纯度: 99.4% CAS No.: 241473-69-8
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价

产品描述

Reslizumab (Sch 55700) 是一种靶向人白介素 5 (IL-5) 的人源化单克隆抗体,用于研究嗜酸性粒细胞性哮喘,可有效阻断 IL-5 的功能,并对人 IL-5 具有高结合亲和力,在 Biacore 表面等离振子共振和动力学排斥分析中 KD 值分别为 109 pM 和 4.3 pM。

生物实验数据

生物活性 Reslizumab (Sch 55700) is a humanized monoclonal antibody targeting human interleukin-5 (IL-5) for the study of eosinophilic asthma that effectively blocks IL-5 function and exhibits high binding affinity for human IL-5, with KD values of 109 pM and 4.3 pM in Biacore surface plasmon resonance and kinetic exclusion assays, respectively.
IC50 & Target IL-5:91.1 pM, Ba/F3 cells:0.5 nM, IL-5 (human):20 pM (Kd), IL-5 (human):109 pM (KD)
体外研究
(In Vitro)

Reslizumab (Sch 55700) (0-10 nM, 48 h) inhibits IL-5-dependent cell proliferation, with an IC50 value of approximately 91.1pM.

Cell Proliferation Assay

Cell Line: Human erythroleukemic TF-1 cell line
Concentration: 0-10 nM
Incubation Time: 48 h
Result: Showed antiproliferative activity with an IC50 of 91.1 pM.
体内研究
(In Vivo)

Reslizumab (Sch 55700) (0-10 mg/kg; i.p. or i.m.) inhibits pulmonary eosinophilia in a dose-dependent manner in allergic mice.
Reslizumab (0.03-30 mg/kg; i.p.) inhibits both the pulmonary eosinophilia and airway hyperresponsiveness, and at 30 mg/kg, i.p. inhibits allergic, but not histamine-induced bronchoconstriction in allergic guinea pigs.
Reslizumab (0.1-1 mg/kg; i.p.) blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs.
Reslizumab (0.3 mg/kg; i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months in allergic cynomolgus monkeys.

Animal Model: Male B6D2F1/J mice weighing 20−25 g, sensitized by an intraperitoneal injection of 0.5 ml of alum-precipitated antigen (8 µg of ovalbumin (OVA) adsorbed to 2 mg of aluminum hydroxide gel in saline vehicle)
Dosage: 0−10 mg/kg
Administration: Intraperitoneal or intramuscular injection (For studies involving i.p. dose-response and i.m. evaluation, the antibody was given 2 h before OVA challenge. For experiments involving duration of activity, the antibody was given at times of 2 h or 4, 6, 8 or 12 weeks before antigen challenge.)
Result: Inhibited the influx of eosinophils into the lungs for a long time (up to 8 weeks after administration of 10 mg/kg and for up to 4 weeks after administration of 2 mg/kg. Demonstrated an anti-inflammatory activity that was additive to that of oral Prednisolone (MS-H48362).
Clinical Trial
NCT NumberSponsorConditionStart DatePhase
NCT03074942Sociedad Espa?ola de Neumología y Cirugía Torácica|Teva Pharmaceuticals USA
Severe Asthma
2017-04-20PHASE2
NCT02501629Teva Branded Pharmaceutical Products R&D, Inc.
Asthma|Elevated Blood Eosinophils|Oral Corticosteroid Dependence
2015-09-29PHASE3
NCT02559791McMaster University|Teva Pharmaceuticals USA|St. Joseph´s Healthcare Hamilton
Severe Persistent Asthma|Eosinophilic Bronchitis
2015-10PHASE2|PHASE3
性状 液体
颜色 Colorless to light yellow

化学信息

CAS No. 241473-69-8
别名 瑞利珠单抗; Sch 55700; CDP-835; JES1-39D10

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础